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1. The different mechanisms by which autoantibodies alter synaptic transmission likely impact the 
widespread function of neurons and neural networks, culminating in serious mental (and 
neurological) disturbances. (this thesis) 
2. The burden of mental disorders continues to grow with significant impacts on health and major 
social, human rights and economic consequences in all countries of the world.	(World Health 
Organization) 
3. Autoantibodies to the NMDA receptor have been described in multiple different neurological 
disorders. The clinical and pathological significance of these antibodies depend on the IgG 
subclass, target subunit of the receptor, and presence of antibodies in the CSF. (Dalmau et al. 
Physiol Rev., 2017) 
4. Cross-validated studies using different detection methods confirmed that pathogenic 
autoantibodies targeting neuronal surface antigens are very rare in psychotic disorders without any 
form of neurological manifestation. (this thesis)  
5. Over the past decades, a sharp increase in autoimmune diseases has been noted worldwide. The 
cumulative prevalence of autoimmune diseases caused by autoantibodies is well over 2.5% of the 
population. (Ludwig R.J. et al., Front Immunol. 2017) 
6. Manipulating the signalling path of these proteins by enhancing MuSK activation, one could 
improve the motor function and correct neuromuscular defects not only in myasthenia gravis but 
also in many other disorders of the neuromuscular junction. (this thesis) 
7. The rapid ixazomib-induced depletion of plasma cells and thus of total IgG and AChR 
autoantibodies we observed in this study provides the basis for a clinical trial in AChR-MG patients. 
(this thesis) 
8. A challenging strategy is to selectively deplete pathogenic long-lived plasma cells in an 
autoantigen-specific manner without removing long-lived plasma cells that provide protective 
humoral memory. (Hiepe, F. and Radbruch, A.	Nat Rev Nephrol.	2016) 
9. Pre-clinical studies are needed in order to formulate hypotheses that justify clinical trials. Without 
these preliminary studies in vitro and in vivo in selected animal species it would be unethical to test 
still unproven chemicals in humans. (Garattini S and Grignaschi G. European Journal of Internal 
Medicine, 2017) 
10. Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that 
we may fear less. (Marie Curie) 
